ARC-19499

ARC-19499 is an investigational aptamer drug developed for the treatment of hemophilia A and B. It functions as a procoagulant by specifically inhibiting tissue factor pathway inhibitor (TFPI), a key negative regulator of the extrinsic coagulation pathway. By binding tightly to TFPI, ARC-19499 blocks its inhibition of both factor Xa and the tissue factor/factor VIIa complex, thereby enabling clot initiation and propagation via the extrinsic pathway. This mechanism allows correction of thrombin generation in hemophilia plasma and restoration of clotting in FVIII-neutralized whole blood. Preclinical studies demonstrated that ARC-19499 can restore normal clotting times in animal models with induced hemophilia[5][7]. The drug has been evaluated in first-in-human clinical trials for safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with hemophilia[1][2][4][9].